A medical tourism campaign touting San Diego’s hospitals, genomics companies and sunny weather is trying to find its groove.
Financing rounds since 2013 have grown larger in San Diego life sciences. A look at annual median deal size shows an increase, from early-stage seed financing to Series A, C and D rounds. Only Series B rounds have remained flat in recent years.
Adamis Pharmaceuticals’ epipen alternative will launch nationally in the first quarter of next year, the company said in a recent update.
San Diego saw seven IPOs in 2018, largely dominated by life sciences companies.
San Diego-based Neurocrine’s drug for Tourette syndrome failed to meet its primary goal in a mid-stage clinical trial, the company reported Dec. 12.
The San Diego Business Journal frequently chronicles local funding rounds and the big dreams that accompany them. But what about the largest venture capital sources locally?
Recently proposed legislation would further push back a 2.3 percent excise tax on medical device makers, San Diego’s ResMed, NuVasive and Ra Medical Systems among them.
HEALTH: Grossmont Makes Move; Palomar Considers Election Change
Under the threat of a lawsuit from a Malibu attorney, one San Diego hospital district is moving to a new type of election system, while another will consider doing so.
Pharmaceutical behemoth Pfizer is set to close a South San Francisco site and relocate 100 jobs to its research and development campus in La Jolla.
Human Longevity Inc.’s latest valuation: $310 million, down more than 80 percent from early 2017, according to the Wall Street Journal.
Oxeia Leading the Pack on Potential Concussion Treatments
Precision health factors in a person’s genes, medical history, environment and more for diagnosis and treatment.
LunaDNA’s first-of-its-kind platform giving shares for contributing DNA data got approval earlier this week from the U.S. Securities and Exchange Commission.
Biogen exercised a licensing option and will pay Carlsbad’s Ionis Pharmaceuticals $35 million for a drug candidate aimed at amyotrophic lateral sclerosis, or ALS.
ViaCyte recently hauled in an $80 million Series D round to advance therapies that the company called a potential “functional cure” for Type 1 diabetes patients.